Literature DB >> 23187845

Surgical palliation of pancreatic cancer.

Claudius Conrad1, Keith D Lillemoe.   

Abstract

The surgical palliation of pancreatic cancer remains an important component of the treatment of this disease. The introduction of a new aggressive and effective chemotherapy regimen (FOLFIRINOX), interdisciplinary palliative care, and minimally invasive approaches for providing palliation are all factors that expand the role of the surgeon in the care of patients with unresectable disease. Currently, the role of the surgeon in the palliation of pancreatic cancer is (1) to identify patients with incurable disease (either preoperatively or intraoperatively), (2) to determine the optimal palliative technique to optimize results and preserve resources, and (3) to perform palliation of symptoms with low morbidity and mortality. The 3 most common symptoms of pancreatic cancer requiring surgical palliation are obstructive jaundice, gastric outlet obstruction, and tumor-associated pain. It is important that the surgeon recognizes the full range of surgical and nonoperative techniques available and contributes to the decision making as to the most appropriate method for each individual patient.

Entities:  

Mesh:

Year:  2012        PMID: 23187845     DOI: 10.1097/PPO.0b013e3182797dfe

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  6 in total

1.  Overuse of surgery in patients with pancreatic cancer. A nationwide analysis in Italy.

Authors:  Gianpaolo Balzano; Giovanni Capretti; Giuditta Callea; Elena Cantù; Flavia Carle; Raffaele Pezzilli
Journal:  HPB (Oxford)       Date:  2016-02-05       Impact factor: 3.647

2.  Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.

Authors:  Alison Chan; Ioannis Prassas; Apostolos Dimitromanolakis; Randall E Brand; Stefano Serra; Eleftherios P Diamandis; Ivan M Blasutig
Journal:  Clin Cancer Res       Date:  2014-09-19       Impact factor: 12.531

3.  Utilization and trends in palliative therapy for stage IV pancreatic adenocarcinoma patients: a U.S. population-based study.

Authors:  Audrey S Kulaylat; Katelin A Mirkin; Christopher S Hollenbeak; Joyce Wong
Journal:  J Gastrointest Oncol       Date:  2017-08

4.  Roux-en-Y duodenojejunostomy improves gastric emptying in experimental obstruction of the distal duodenum.

Authors:  Sławomir Mrowiec; Krzysztof Jonderko; Zygmunt Górka; Paweł Lampe; Anna Kasicka-Jonderko; Joanna Kołodziejczak-Nalewajka; Katarzyna Kuśnierz; Marek Olakowski
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

Review 5.  Current role of palliative interventions in advanced pancreatic cancer.

Authors:  Chelsey C Ciambella; Rachel E Beard; Thomas J Miner
Journal:  World J Gastrointest Surg       Date:  2018-10-27

6.  Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for early‑stage pancreatic ductal adenocarcinoma.

Authors:  Chengkun Yang; Tingdong Yu; Zhengqian Liu; Xinping Ye; Xiwen Liao; Xiangkun Wang; Chuangye Han; Guangzhi Zhu; Wei Qin; Tao Peng
Journal:  Oncol Rep       Date:  2019-04-24       Impact factor: 3.906

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.